TK inhibitors being tested against DTC in clinical trials include motesanib diphosphate, axitinib, gefitinib, sorafenib and sunitinib.
Thyroid cancer accounts for fewer than 1% of all human tumours and is much more prevalent among females than males. The incidence of thyroid cancer (mainly differentiated) is one of the most rapidly increasing among human cancers, at least in the US. 1 This phenomenon is mainly due to an increase in the papillary histotype, which showed a 2.9-fold increase per year. The increase is attributable to better detection of small papillary carcinomas as a result of improved diagnostic accuracy (neck ultrasound and fine-needle aspiration cytology [FNAC] ). It is a common experience in thyroid cancer referral centres that nearly 60-80% of thyroid carcinomas detected nowadays are micropapillary thyroid carcinomas (less than 1cm in size) carrying an excellent long-term prognosis. 2, 3 Despite an increasing incidence, the mortality from thyroid cancer in general and from papillary thyroid cancer in particular remained stable (0.5 deaths per 100,000 in both 1973 and 2002). 1 In addition, in recent decades the clinical presentation of differentiated thyroid cancer (DTC) has been changing from advanced cases requiring intense treatment and surveillance to cancer detected by fortuitous neck ultrasonography requiring less aggressive treatment and follow-up. Diagnostic and treatment tools have also improved in recent years (sensitive assays for serum thyroglobulin measurement, neck ultrasound and recombinant human thyroid stimulating hormone
[rhTSH]), thus allowing for less invasive procedures for the patients.
Altogether, these considerations dictate the need for applying the more effective and less expensive procedures able to guarantee the best management and the best quality of life for a cancer that, despite having an intrinsic low mortality, requires life-long follow-up.
Diagnosis of Thyroid Cancer
Thyroid cancer presents as a thyroid nodule detected by palpation and more frequently by neck ultrasound. While thyroid nodules are frequent (4-50% depending on the diagnostic procedures and the age of the patient), thyroid cancer is rare (only 5% of all thyroid nodules). thyroid scan, surgery should be considered. [4] [5] [6] [7] Considering that the prevalence of indeterminate FNAC is significant (10-25%), several molecules involved in the carcinogenic process have been proposed as markers of thyroid malignancy, but none is recommended because of insufficient data. 8, 9 
Initial Treatment
The initial treatment for DTC is total or near-total thyroidectomy whenever the diagnosis is made before surgery, regardless of nodule size. Less extensive surgical procedures may be accepted in cases of unifocal DTC diagnosed at finally histology after surgery performed for benign thyroid disorders provided that the tumour is small, intrathyroidal and of favourable histological type (classic papillary or follicular variant of papillary or minimally invasive follicular). Surgery is usually followed by the administration of 131 I activities aimed at ablating any remnant thyroid tissue and eventually microscopic residual tumour. This procedure decreases the risk of locoregional recurrence and facilitates the long-term surveillance based on serum Tg measurement and diagnostic radioiodine whole body scan (WBS).
In addition, the high activity of 131 I allows a highly sensitive post-therapeutic WBS to be obtained. Radioiodine ablation is recommended in high-and low-risk patients, while there is no indication in very low-risk patients (those with unifocal T1 tumours less than 1cm in size, with favourable histology, no extrathyroidal extension and lymph node metastases). 6 Advances in the Diagnosis and Management of Differentiated Thyroid Cancer
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Advances in the Diagnosis and Management of Differentiated Thyroid Cancer
Traditionally, withdrawal of thyroid hormone has been used to optimise the trapping and retention of radioiodine by increasing endogenous TSH levels. The consequent state of hypothyroidism is unpleasant for most patients and sometimes results in marked morbidity and impairment of quality of life. 10 
Short-term Follow-up
Six to 12 months after initial treatment, follow-up aims to ascertain whether the patient is free of disease, and is based on physical examination, neck ultrasound, serum Tg measurement and diagnostic 131 I WBS. 6, 7 Currently, most of the patients (nearly 80%) will be in complete remission as indicated by no clinical evidence of residual disease, unremarkable neck ultrasound and undetectable basal and stimulated serum Tg (in the absence of serum Tg antibodies).
A diagnostic 131 I WBS does not add any clinical information in this setting and may be omitted. In association with a negative posttherapy WBS obtained at the time of thyroid remnant ablation, these findings are sufficient to classify the patient as free of disease, and the rate of subsequent recurrence in this group is very low (<1.0% at 10 years). 16, 17 These patients may be shifted from suppressive to replacement LT4 therapy, with the goal of maintaining serum TSH level within the normal range. A significant proportion of patients defined as high-risk at the time of diagnosis may appear to be free of disease at their first follow-up after initial treatment. However, the risk of relapse in the long term may be significant; therefore, it is advisable to maintain these patients on suppressive doses of LT4 therapy (TSH around 0.1µUI/ml) for a further three to five years. 18 
Long-term Follow-up
The subsequent follow-up of patients considered to be free of disease 
Targeted Therapy
Diffuse metastatic disease refractory to radioiodine may be treated with systemic chemotherapy, but unfortunately the results are usually very poor and disappointing. 6 Other currently available therapies are subjects with DTC and tolerable and manageable toxicities. 23 Axitinib, an agent that targets all VEGF receptors, PDGFR-β and KIT, was evaluated in a single-arm study of 60 subjects with advanced thyroid cancer and reported PR and SD rates in 13 patients (22%) and in 30 patients (50%), respectively. 24 Gefitinib, a small-molecule inhibitor of the EGFR tyrosine kinase, was used to treat 27 patients with radioiodine-refractory, locally advanced or metastatic thyroid cancer of different histotypes, including papillary, follicular, medullary and Hurthle cell carcinoma.
No objective responses were observed, although tumour reduction that did not meet the criteria for partial response was achieved in 32% of the patients and five patients with stable disease had a decrease in thyroglobulin to <90% of baseline. In addition, stabilisation of the disease was obtained in 48, 24 and 12% of the patients after three, six and 12 months of treatment, respectively. The authors interpreted these results as modest but still suggestive of a biological effect of the drug. 25 The administration of sorafenib in 30 patients with metastatic, iodine-refractory thyroid carcinoma determined a PR in seven patients (23%), a SD in 16 patients (53%) and showed an overall clinical benefit rate (partial response plus stable disease) of 77%, a median progression-free survival of 79 weeks and an overall acceptable safety profile. 26 Sunitinib is a inhibitor of VEGFR-1, VEGFR-2, foetal liver tyrosine kinase receptor 3 (FLT3), KIT and PDGFR in both biochemical and cellular assays, but the response rate in clinical trials is still being evaluated.
Conclusion
The preliminary results of these trials are promising and indicate that targeted therapy might become the first-line treatment of metastatic refractory thyroid cancer patients in the near future. I
